

DORSET MEDICINES ADVISORY GROUP

Recommendation Summary



**Dorset
Clinical Commissioning Group**

The Dorset Medicines Advisory Group (DMAG) represents the four provider Trusts and GPs within the Clinical Commissioning Group (CCG). It provides recommendations to the CCG's clinical commissioning committee (CCC) on the prescribing and commissioning of medicines.

Summary of recommendations considered at a meeting of the group on 18th September 2018. Formulary entries and associated documents can be accessed at www.dorsetformulary.nhs.uk.

PRODUCT	DECISION	COMMENTS
1. Products re-categorised		
Trehalose 3%, Sodium Hyaluronate 0.15% drops, and with Carbomer 0.25% for gel. (Thealoz Duo®)	Amber, from red	For those patients who have severe dry eyes as an alternative to Sodium hyaluronate 0.2% or 0.4%, as it provides a combination of lubricants at a lower cost.
Bismuth subsalicylate tablets	Green, from red	This re-categorisation would enable the use of the tablets in line with Public Health England guidance on the management of Helicobacter pylori in dyspepsia. As use is within the second line treatment regime for penicillin allergic patient's numbers are likely to be small
Tioconazole	Non-formulary from green	To align with NICE Clinical Knowledge Summary for fungal nail infections
Levofloxacin eye drops and moxifloxacin eye drops	Amber, from red	For a very small number of patients with significant corneal disease who might require the drops for up to six months. It would be the responsibility of the consultant to advise of the length of course and "stopping date" to the relevant prescriber
Co-phenotrope	Non-formulary from green	Discontinued
Alfacalcidol	Amber to Amber with SCG	To ensure appropriate monitoring of all patients in primary care
NHS England "Guidance on conditions for which over the counter items should not routinely be prescribed in primary care"	Various formulary amendments approved	Formulary entries will be annotated with self-care icon, see table below.

PRODUCT	DECISION	COMMENTS
2. New requests		
Freestyle Libre for paediatric patients	For health community consideration, commencing with CCC Red for initial six months progressing to amber if positive patient outcomes	The intended patient cohort is children and young people where they: <ul style="list-style-type: none"> • Already blood glucose test 8 times or more daily (breakeven for cost). • Have an HbA1c of 68 mmol/mol (8.5%) or higher, or unable to achieve this without disabling hypoglycaemia, thereby meeting pump referral criteria. FGM to be used as an alternative to pump referral and reconsidered if started on pump. • Have two or more admissions with DKA in a year, or two or more severe hypoglycaemia episodes. • Are unable to manage without third party assistance and where conventional blood testing difficult, e.g. for behavioural reasons. • Are training or working where constantly dirty hands makes testing impracticable. • Have impaired hypoglycaemia awareness or inability to communicate hypoglycaemia.
Lisdexamfetamine (Elvanse Adult®)	Amber with shared care	In accordance with NICE NG87: https://www.nice.org.uk/guidance/ng87 Further commissioning discussions to be progressed regarding provision of service to adult patients
Injectable antibiotic, ceftazidime-avibactam	Red	
3. Products considered by NICE		
Ixekizumab for psoriatic arthritis	Red in accordance with local pathway	https://www.nice.org.uk/guidance/ta537
4. Miscellaneous recommendations by DMAG		
Wound products (re-categorisation and additions)		<ul style="list-style-type: none"> • K-Three® system (multi layer compression) – to move from non-formulary to formulary as a “green” product to ensure the full multi layer system is available to prescribe. • Mepitel® dressings to be included on formulary as “amber” solely for the management of life threatening acute skin disorders such as toxic epidermal necrolysis (TEN), bullous pemphigoid and vasculitis. Mepitel® remains non-formulary for all other indications. • Entry for Normasol® to be amended to the generic sodium chloride 0.9%.

PRODUCT	DECISION	COMMENTS
		<ul style="list-style-type: none"> • Dressing packs – Nurse-It® to be added to formulary as the brand available on FP10, for those rare occasions where an FP10 is appropriate. A reminder on the guidance on the use of sterile dressing packs to be added to the entry. • Re-categorisation of Zetuvit E® (non sterile) and Zetuvit® (sterile) from “green” to non-formulary
Fluphenazine Decanoate (Modecate®)		Discontinued
Sticker and leaflet produced to reduce telephone calls from care homes for inappropriate treatment of UTIs		To be made available on the formulary
Liraglutide (Saxenda®)	Non-formulary	Approval of commissioning statement to support the non-formulary status of liraglutide (as brand Saxenda®) for weight loss
5. Further Assessment / Evidence Required		
Oxazepam		
6. Expired Documents Reviewed		
<ul style="list-style-type: none"> • Revised shared care guideline for cinacalcet • Shared care guideline for calcitonin • Shared care guideline for denosumab • Shared care guideline and commissioning statement for brimonidine • Guideline for the primary and secondary prevention of osteoporosis • Guideline for prescribing eflornithine (Vaniqa®) for facial hirsutism • Commissioning statement for Omalizumab for previously treated chronic spontaneous urticaria • Commissioning statement for Pigmanorm® 		

Formulary amendments made in line with NHS England “Guidance on conditions for which over the counter items should not routinely be prescribed in primary care”

The formulary working group reviewed the OTC consultation for formulary changes that do not fall under other working groups and recommended the following changes:				
Drug	Change to		Drug	Change to
Silver nitrate	Red		AA enema	Red
Coughs and colds: Benz co., benz tincture	Non-formulary		Headlice products	Green (second line)
Xylometazoline	Red		Abidec and Sytron	Amber (with comment to be initiated only in Secondary care)
Chlorhexidine/ tetracain	Non-formulary		Pregaday	Non-formulary
Docusate sodium ear drops 0.5%	Non-formulary		AA enema	Red
Oclusal, salactol,	Red (used at DCH)		Potassium citrate	Red
Glutarol , verrugon solutions	Red (used at RBH)		Sudocrem	Non-formulary
Olive Oil	Red		Metanium	Non-formulary
Waxsol	Non-formulary		Adcortyl in Orabase	Red
Anusol products	Red		Bonjela	Red

Classification of products:

‘RED’ drugs for hospital use only

‘AMBER with shared care’ drugs suitable for use with shared care arrangements

‘AMBER’ drugs suitable for use without shared care arrangements

‘GREEN’ drugs suitable for prescribing in primary and secondary care

‘Not Recommended’ – drugs not recommended for use in Dorset